Cargando…
Coronary Access and Percutaneous Coronary Intervention Up to 3 Years After Transcatheter Aortic Valve Implantation With a Balloon-Expandable Valve
BACKGROUND: Coronary artery disease and aortic stenosis often coexist. Transcatheter aortic valve implantation (TAVI) has emerged as a valid therapeutic option for younger, lower-risk patients who may eventually require coronary artery disease treatment. Thus, post-TAVI coronary access (CA) and perc...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373469/ https://www.ncbi.nlm.nih.gov/pubmed/32580586 http://dx.doi.org/10.1161/CIRCINTERVENTIONS.120.008972 |
_version_ | 1783561498888503296 |
---|---|
author | Tarantini, Giuseppe Nai Fovino, Luca Le Prince, Pascal Darremont, Olivier Urena, Marina Bartorelli, Antonio L. Vincent, Flavien Hovorka, Tomas Alcalá Navarro, Yasmina Dumonteil, Nicolas Ohlmann, Patrick Wendler, Olaf |
author_facet | Tarantini, Giuseppe Nai Fovino, Luca Le Prince, Pascal Darremont, Olivier Urena, Marina Bartorelli, Antonio L. Vincent, Flavien Hovorka, Tomas Alcalá Navarro, Yasmina Dumonteil, Nicolas Ohlmann, Patrick Wendler, Olaf |
author_sort | Tarantini, Giuseppe |
collection | PubMed |
description | BACKGROUND: Coronary artery disease and aortic stenosis often coexist. Transcatheter aortic valve implantation (TAVI) has emerged as a valid therapeutic option for younger, lower-risk patients who may eventually require coronary artery disease treatment. Thus, post-TAVI coronary access (CA) and percutaneous coronary intervention are expected to increase. The purpose of this study was to retrospectively evaluate patients who were enrolled in the SOURCE 3 (SAPIEN 3 Aortic Bioprosthesis European Outcome) European registry for treatment with the balloon-expandable SAPIEN 3 transcatheter heart valve and underwent CA with or without percutaneous coronary intervention after TAVI. METHODS: Baseline characteristics and clinical outcomes of patients with or without CA up to 3 years after TAVI were compared. A Kaplan-Meier estimate with a univariate model determined the impact of CA on cardiac mortality. RESULTS: Of 1936 TAVI patients (mean age 81.6 years, 52% male), 68 (3.5%) had CA within 3 years (mean 441±332 days) after TAVI. At baseline, the logistic EuroSCORE was similar (20.2% versus 18.3%, P=0.2, CA and non-CA groups, respectively). Higher rates of coronary artery disease (76.5% versus 50.6%, P<0.001), myocardial infarction (20.6% versus 11.5%, P=0.03) and previous coronary artery bypass graft (22.1% versus 11.0%, P=0.01) were present in the CA group. In 100% of patients, CA was successfully achieved. The clinical success of percutaneous coronary intervention was 97.9%. Cardiovascular mortality was numerically higher in patients with CA than in those without CA. CONCLUSIONS: In the large SOURCE 3 European registry, CA was needed at 3-year follow-up after TAVI with a balloon-expandable valve in 3.5% of patients and was successful in all patients. The clinical success of percutaneous coronary intervention was 97.9%. REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02698956. |
format | Online Article Text |
id | pubmed-7373469 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-73734692020-08-05 Coronary Access and Percutaneous Coronary Intervention Up to 3 Years After Transcatheter Aortic Valve Implantation With a Balloon-Expandable Valve Tarantini, Giuseppe Nai Fovino, Luca Le Prince, Pascal Darremont, Olivier Urena, Marina Bartorelli, Antonio L. Vincent, Flavien Hovorka, Tomas Alcalá Navarro, Yasmina Dumonteil, Nicolas Ohlmann, Patrick Wendler, Olaf Circ Cardiovasc Interv Original Articles BACKGROUND: Coronary artery disease and aortic stenosis often coexist. Transcatheter aortic valve implantation (TAVI) has emerged as a valid therapeutic option for younger, lower-risk patients who may eventually require coronary artery disease treatment. Thus, post-TAVI coronary access (CA) and percutaneous coronary intervention are expected to increase. The purpose of this study was to retrospectively evaluate patients who were enrolled in the SOURCE 3 (SAPIEN 3 Aortic Bioprosthesis European Outcome) European registry for treatment with the balloon-expandable SAPIEN 3 transcatheter heart valve and underwent CA with or without percutaneous coronary intervention after TAVI. METHODS: Baseline characteristics and clinical outcomes of patients with or without CA up to 3 years after TAVI were compared. A Kaplan-Meier estimate with a univariate model determined the impact of CA on cardiac mortality. RESULTS: Of 1936 TAVI patients (mean age 81.6 years, 52% male), 68 (3.5%) had CA within 3 years (mean 441±332 days) after TAVI. At baseline, the logistic EuroSCORE was similar (20.2% versus 18.3%, P=0.2, CA and non-CA groups, respectively). Higher rates of coronary artery disease (76.5% versus 50.6%, P<0.001), myocardial infarction (20.6% versus 11.5%, P=0.03) and previous coronary artery bypass graft (22.1% versus 11.0%, P=0.01) were present in the CA group. In 100% of patients, CA was successfully achieved. The clinical success of percutaneous coronary intervention was 97.9%. Cardiovascular mortality was numerically higher in patients with CA than in those without CA. CONCLUSIONS: In the large SOURCE 3 European registry, CA was needed at 3-year follow-up after TAVI with a balloon-expandable valve in 3.5% of patients and was successful in all patients. The clinical success of percutaneous coronary intervention was 97.9%. REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02698956. Lippincott Williams & Wilkins 2020-06-25 /pmc/articles/PMC7373469/ /pubmed/32580586 http://dx.doi.org/10.1161/CIRCINTERVENTIONS.120.008972 Text en © 2020 The Authors. Circulation: Cardiovascular Interventions is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made. |
spellingShingle | Original Articles Tarantini, Giuseppe Nai Fovino, Luca Le Prince, Pascal Darremont, Olivier Urena, Marina Bartorelli, Antonio L. Vincent, Flavien Hovorka, Tomas Alcalá Navarro, Yasmina Dumonteil, Nicolas Ohlmann, Patrick Wendler, Olaf Coronary Access and Percutaneous Coronary Intervention Up to 3 Years After Transcatheter Aortic Valve Implantation With a Balloon-Expandable Valve |
title | Coronary Access and Percutaneous Coronary Intervention Up to 3 Years After Transcatheter Aortic Valve Implantation With a Balloon-Expandable Valve |
title_full | Coronary Access and Percutaneous Coronary Intervention Up to 3 Years After Transcatheter Aortic Valve Implantation With a Balloon-Expandable Valve |
title_fullStr | Coronary Access and Percutaneous Coronary Intervention Up to 3 Years After Transcatheter Aortic Valve Implantation With a Balloon-Expandable Valve |
title_full_unstemmed | Coronary Access and Percutaneous Coronary Intervention Up to 3 Years After Transcatheter Aortic Valve Implantation With a Balloon-Expandable Valve |
title_short | Coronary Access and Percutaneous Coronary Intervention Up to 3 Years After Transcatheter Aortic Valve Implantation With a Balloon-Expandable Valve |
title_sort | coronary access and percutaneous coronary intervention up to 3 years after transcatheter aortic valve implantation with a balloon-expandable valve |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373469/ https://www.ncbi.nlm.nih.gov/pubmed/32580586 http://dx.doi.org/10.1161/CIRCINTERVENTIONS.120.008972 |
work_keys_str_mv | AT tarantinigiuseppe coronaryaccessandpercutaneouscoronaryinterventionupto3yearsaftertranscatheteraorticvalveimplantationwithaballoonexpandablevalve AT naifovinoluca coronaryaccessandpercutaneouscoronaryinterventionupto3yearsaftertranscatheteraorticvalveimplantationwithaballoonexpandablevalve AT leprincepascal coronaryaccessandpercutaneouscoronaryinterventionupto3yearsaftertranscatheteraorticvalveimplantationwithaballoonexpandablevalve AT darremontolivier coronaryaccessandpercutaneouscoronaryinterventionupto3yearsaftertranscatheteraorticvalveimplantationwithaballoonexpandablevalve AT urenamarina coronaryaccessandpercutaneouscoronaryinterventionupto3yearsaftertranscatheteraorticvalveimplantationwithaballoonexpandablevalve AT bartorelliantoniol coronaryaccessandpercutaneouscoronaryinterventionupto3yearsaftertranscatheteraorticvalveimplantationwithaballoonexpandablevalve AT vincentflavien coronaryaccessandpercutaneouscoronaryinterventionupto3yearsaftertranscatheteraorticvalveimplantationwithaballoonexpandablevalve AT hovorkatomas coronaryaccessandpercutaneouscoronaryinterventionupto3yearsaftertranscatheteraorticvalveimplantationwithaballoonexpandablevalve AT alcalanavarroyasmina coronaryaccessandpercutaneouscoronaryinterventionupto3yearsaftertranscatheteraorticvalveimplantationwithaballoonexpandablevalve AT dumonteilnicolas coronaryaccessandpercutaneouscoronaryinterventionupto3yearsaftertranscatheteraorticvalveimplantationwithaballoonexpandablevalve AT ohlmannpatrick coronaryaccessandpercutaneouscoronaryinterventionupto3yearsaftertranscatheteraorticvalveimplantationwithaballoonexpandablevalve AT wendlerolaf coronaryaccessandpercutaneouscoronaryinterventionupto3yearsaftertranscatheteraorticvalveimplantationwithaballoonexpandablevalve |